John Greim/LightRocket via Getty Images(NEW YORK) — Bristol-Myers Squibb announced on Thursday it is purchasing fellow drugmaker Celgene in a cash and stock deal valued at approximately $74 billion. Per the terms of the agreement, Celgene shareholders will receive one share of Bristol-Myers Squibb and $50 for each share of Celgene. That amounts to $102.43 …
Jan 03
Bristol-Myers Squibb to acquire Celgene in $74B deal
